Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 3/20 | 0.50 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.38 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL841961 | 0.87 | ADRA2A (0.55) | ADRA2AADRA2BADRA2CTAAR1SMN1; SMN2 | |
| SCHEMBL9816188 | 0.78 | ADRA2A (0.53) | ADRA2AADRA2BADRA2CTAAR1SMN1; SMN2 | |
| SCHEMBL2241797 | 0.78 | ADRA2A (0.53) | ADRA2AADRA2BADRA2CTAAR1PTGS1 | |
| SCHEMBL23465175 | 0.76 | ADRA2A (0.51) | ADRA2AADRA2BADRA2CTAAR1SMN1; SMN2 | |
| SCHEMBL11243180 | 0.76 | TAAR1 (0.52) | ADRA2AADRA2BADRA2CTAAR1SMN1; SMN2 | |
| SCHEMBL17533383 | 0.75 | — | — | |
| SCHEMBL2886695 | 0.73 | — | — | |
| SCHEMBL921584 | 0.72 | — | — | |
| SCHEMBL25895349 | 0.71 | ADRA2A (0.46) | ADRA2AADRA2BADRA2CTAAR1SMN1; SMN2 | |
| SCHEMBL144121 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1320521-B1 | 2-THIOCARBAMOYLOXY AND 2-CARBAMOYLOXY DERIVATIVES OF CYCLOPENTYL-HEPTAN(EN)OIC ACID AS THERAPEUTIC AGENTS | ALLERGAN INC (US) | 2004-07-21 | — | — | EP | disclosed |
| EP-1320521-A1 | 2-THIOCARBAMOYLOXY AND 2-CARBAMOYLOXY DERIVATIVES OF CYCLOPENTYL-HEPTAN(EN)OIC ACID AS THERAPEUTIC AGENTS | Allergan, Inc. (US) | 2003-06-25 | — | — | EP | disclosed |
| US-20020058692-A1 | CYCLOPENTANE HEPTAN(ENE)OIC ACID, 2-THIOCARBAMOYLOXY AND 2-CARBAMOYLOXY COMPOUNDS AS THERAPEUTIC AGENTS | ALLERGAN SALES, INC. | 2002-05-16 | — | — | US | disclosed |
| US-6380250-B1 | THERAPY OF OCULAR HYPERTENSION WHICH COMPRISES ADMINISTERING CYCLOPENTANE HEPTAN(ENE)OIC ACID OR ITS 2-THIOCARBAMOYLOXY AND 2-CARBAMOYLOXY DERIVATIVES | ALLERGAN SALES, INC. | 2002-04-30 | — | — | US | disclosed |
| US-6380251-B1 | THERAPY OF OCULAR HYPERTENSION WHICH COMPRISES ADMINISTERING CYCLOPENTANE HEPTAN(ENE)OIC ACID OR ITS 2-THIOCARBAMOYLOXY AND 2-CARBAMOYLOXY DERIVATIVES | ALLERGAN SALES, INC. | 2002-04-30 | — | — | US | disclosed |
| WO-2002026704-A1 | 2-THIOCARBAMOYLOXY AND 2-CARBAMOYLOXY DERIVATIVES OF CYCLOPENTYL-HEPTAN(ENE)OIC ACID AS THERAPEUTIC AGENTS | ALLERGAN INC. (US) | 2002-04-04 | — | — | WO | disclosed |
| US-6291522-B1 | OCULAR HYPOTENSIVES. | ALLERGAN SALES, INC. | 2001-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058692-A1 | CYCLOPENTANE HEPTAN(ENE)OIC ACID, 2-THIOCARBAMOYLOXY AND 2-CARBAMOYLOXY COMPOUNDS AS THERAPEUTIC AGENTS | OXER1, ENY2, CYP8B1 | ADRA2A 189/4885ADRA2B 134/4885ADRA2C 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.